rs113488022
|
|
Colorectal Carcinoma
|
T |
0.900 |
CausalMutation
|
CLINVAR |
|
|
|
rs113488022
|
|
Papillary thyroid carcinoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
rs113488022
|
|
Cardio-facio-cutaneous syndrome
|
T |
0.710 |
CausalMutation
|
CLINVAR |
|
|
|
rs113488022
|
|
ASTROCYTOMA, LOW-GRADE, SOMATIC
|
T |
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
rs113488022
|
|
Nongerminomatous Germ Cell Tumor
|
T |
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
rs113488022
|
|
Gastrointestinal Stromal Tumors
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs113488022
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs113488022
|
|
ovarian neoplasm
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Missense mutations of the BRAF gene in human lung adenocarcinoma.
|
12460919 |
2002 |
rs113488022
|
|
Carcinoma of lung
|
T |
0.750 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi.
|
12447372 |
2003 |
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These resu</span>lts suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC.
|
12881714 |
2003 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The most common mutation in CM was V599E, but a novel point mutation (L596Q) was identified in two cases and an in-frame deletion/insertion (VKSRWK599-604D) was discovered in one case.
|
14522897 |
2003 |
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Determinants of BRAF mutations in primary melanomas.
|
14679157 |
2003 |
rs113488022
|
|
Cutaneous Melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The activating V599E mutation accounted for 80% of all mutations detected in cutaneous melanoma cell lines.
|
12917419 |
2003 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The activating V599E mutation accounted for 80% of all mutations detected in cutaneous melanoma cell lines.
|
12917419 |
2003 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Thus, when present, BRAF(V599E) appears to be essential for melanoma cell viability and transformation and, therefore, represents an attractive therapeutic target in the majority of melanomas that harbor the mutation.
|
14500344 |
2003 |
rs113488022
|
|
Cutaneous Melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The most common mutation in CM was V599E, but a novel point mutation (L596Q) was identified in two cases and an in-frame deletion/insertion (VKSRWK599-604D) was discovered in one case.
|
14522897 |
2003 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutations in the BRAF gene causing a V599E amino acid substitution that enhance the kinase activity have been described in >60% of cutaneous melanomas and premalignant melanocytic lesions.
|
14522889 |
2003 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In addition we have searched for exon 15 BRAF mutations in 24 samples of secondary melanoma from 22 cases of sporadic melanoma and detected the 1796T>A BRAF mutation which leads to a substitution of valine by glutamic acid at position 599 (V599E) in six samples.
|
12619120 |
2003 |